Moldenhauer; Gerhard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Moldenhauer; Gerhard.The latest application filed is for "novel means and methods for treating hbv infection and associated conditions".

Company Profile

1.15.15

Moldenhauer; Gerhard - Bad Arolsen DE
Moldenhauer; Gerhard - Heidelberg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Means and methods for treating HBV infection and associated conditions Grant 10,730,943 - Protzer , et al.	2020-08-04
Trispecific binding molecules for treating HBV infection and associated conditions Grant 10,711,054 - Protzer , et al.	2020-07-14
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy Grant 10,513,559 - Faulstich , et al. Dec	2019-12-24
Binding molecules, especially antibodies, binding to L1CAM (CD171) Grant 10,400,037 - Altevogt , et al. Sep	2019-09-03
Novel Means And Methods For Treating Hbv Infection And Associated Conditions App 20180362649 - Protzer; Ulrike ; et al.	2018-12-20
Means and methods for treating HBV infection and associated conditions Grant 10,059,767 - Protzer , et al. August 28, 2	2018-08-28
Trispecific Binding Molecules For Treating Hbv Infection And Associated Conditions App 20180079798 - PROTZER; Ulrike ; et al.	2018-03-22
Binding Molecules, Especially Antibodies, Binding To L1cam (cd171) App 20170306015 - ALTEVOGT; Peter ; et al.	2017-10-26
B7-H6 therapeutically active monoclonal antibody against B7-H6 polypeptide Grant 9,676,855 - Cerwenka , et al. June 13, 2	2017-06-13
Novel Means And Methods For Treating Hbv Infection And Associated Conditions App 20160200798 - Protzer; Ulrike ; et al.	2016-07-14
Amatoxin-armed Therapeutic Cell Surface Binding Components Designed For Tumour Therapy App 20160089450 - FAULSTICH; Heinz ; et al.	2016-03-31
Treatment of tumors using specific anti-L1 antibody Grant 9,260,521 - Kelm , et al. February 16, 2	2016-02-16
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy Grant 9,233,173 - Faulstich , et al. January 12, 2	2016-01-12
B7-h6 Therapeutically Active Monoclonal Antibody Against B7-h6 Polypeptide App 20140341915 - Cerwenka; Adelheid ; et al.	2014-11-20
Method for producing protein libraries and for selecting proteins from said libraries Grant 8,771,960 - Breitling , et al. July 8, 2	2014-07-08
Treatment Of Tumors Using Specific Anti-l1 Antibody App 20140120117 - Kelm; Daniela ; et al.	2014-05-01
Treatment of tumors using specific anti-L1 antibody Grant 8,580,258 - Kelm , et al. November 12, 2	2013-11-12
Treatment Of Tumors Using Specific Anti-l1 Antibody App 20120258039 - Gast; Daniela ; et al.	2012-10-11
Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer App 20120213805 - Faulstich; Heinz ; et al.	2012-08-23
Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy App 20120100161 - Faulstich; Heinz ; et al.	2012-04-26
Treatment of tumors using specific anti-L1 antibody Grant 8,138,313 - Kelm , et al. March 20, 2	2012-03-20
Treatment Of Tumors Using Specific Anti-l1 Antibody App 20090162355 - Gast; Daniela ; et al.	2009-06-25
Drop1, a novel marker for carcinogenesis App 20070093436 - Ponstingl; Herwig ; et al.	2007-04-26
Dimeric and multimeric antigen binding structure App 20050079170 - Le Gall, Fabrice ; et al.	2005-04-14
Method for producing protein libraries and for selecting proteins from said libraries App 20050059082 - Breitling, Frank ; et al.	2005-03-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.